Diagenode’s CRISPR/Cas9 polyclonal antibody has been raised against the N-terminus of the Cas9 nuclease, extensively validated and optimized for excellent specificity and high yields in chromatin IP.
The European Regional Development Fund and Wallonia are investing in your
Extension of industrial buildings and new laboratories.
Contact us |
Conditions of sales |
Conditions of purchase |
To ensure you see the information most relevant to you, please select your country.
Please note that your browser will need to be configured to accept cookies.